Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
This is precisely where StockStory comes in - we do the heavy lifting to identify companies with solid fundamentals so you can invest with confidence. Keeping that in mind, here are two mid-cap stocks with huge upside potential and one best left ignored.
One Mid-Cap Stock to Sell:
C.H. Robinson Worldwide (CHRW)
Market Cap: $19.13 billion
Engaging in contracts with tens of thousands of transportation companies, C.H. Robinson (NASDAQ: CHRW) offers freight transportation and logistics services.
Why Are We Hesitant About CHRW?
- Sales tumbled by 5.4% annually over the last two years, showing market trends are working against its favor during this cycle
- High input costs result in an inferior gross margin of 7.4% that must be offset through higher volumes
- Waning returns on capital imply its previous profit engines are losing steam
At $161.79 per share, C.H. Robinson Worldwide trades at 28.9x forward P/E. Read our free research report to see why you should think twice about including CHRW in your portfolio.
Two Mid-Cap Stocks to Buy:
Super Micro (SMCI)
Market Cap: $17.7 billion
Founded in Silicon Valley in 1993 and known for its modular "building block" approach to server design, Super Micro Computer (NASDAQ: SMCI) designs and manufactures high-performance, energy-efficient server and storage systems for data centers, cloud computing, AI, and edge computing applications.
Why Should You Buy SMCI?
- Market share has increased this cycle as its 68.8% annual revenue growth over the last two years was exceptional
- Enormous revenue base of $21.05 billion provides significant distribution advantages
- Free cash flow turned positive over the last five years, showing the company is at an important crossroads
Super Micro is trading at $29.66 per share, or 12.9x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free for active Edge members .
Insulet (PODD)
Market Cap: $20.19 billion
Revolutionizing diabetes care with its tubeless "Pod" technology, Insulet (NASDAQ: PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line.
Why Will PODD Outperform?
- Constant currency growth averaged 26.8% over the past two years, showing it can expand globally regardless of the macroeconomic environment
- Free cash flow margin grew by 32.6 percentage points over the last five years, giving the company more chips to play with
- Returns on capital are growing as management capitalizes on its market opportunities
Insulet’s stock price of $287.64 implies a valuation ratio of 49.8x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free for active Edge members.
High-Quality Stocks for All Market Conditions
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.
